Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Proteomics International LaboratoriesPIQLF 13 Days Sales Outstanding is 107.22 as of Dec. 2025, which is 1% above its 10-year median of 106.55. GuruFocus rates PIQLF with a GF Score™ of 13/100 and a GF Value™ of $0.39 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 841 Biotechnology companies, Proteomics International Laboratories ranks worse than 93.46% on this metric.
PIQLF'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 64.24 Med: 106.55 Max: 460.19
Current: 383.82
During the past 12 years, Proteomics International Laboratories's highest Days Sales Outstanding was 460.19. The lowest was 64.24. And the median was 106.55.
PIQLF's Days Sales Outstanding is ranked worse than 93.46% of 841
companies
in the Biotechnology industry
Industry Median: 68.98
vs PIQLF: 383.82
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Proteomics International Laboratories Days Sales Outstanding Chart
PIQLF vs VRTX, REGN, MRNA: Days Sales Outstanding Comparison
For the Biotechnology subindustry, Proteomics International Laboratories's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Proteomics International Laboratories Days Sales Outstanding vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Proteomics International Laboratories's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Proteomics International Laboratories's Days Sales Outstanding falls into.
Proteomics International Laboratories Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Days Sales Outstanding of 107.22 mean?
Proteomics International Laboratories (PIQLF) has a Days Sales Outstanding of 107.22 as of Dec. 2025. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Proteomics International Laboratories and its competitors. This is near median its historical median of 106.55. Over the past decade, Proteomics International Laboratories' Days Sales Outstanding has ranged from 64.24 to 460.19. According to the industry distribution chart, Proteomics International Laboratories ranks #786 out of 841 companies in the Biotechnology industry, placing it in the top 93.5%.
Is Proteomics International Laboratories' Days Sales Outstanding too high?
Proteomics International Laboratories' current Days Sales Outstanding of 107.22 is near median its 10-year median of 106.55. Over the past 10 years, this metric has ranged from a low of 64.24 to a high of 460.19. The Biotechnology industry median Days Sales Outstanding is 68.98. Proteomics International Laboratories' value of 107.22 is 55.4% above this industry median. Based on the distribution chart, Proteomics International Laboratories ranks #786 out of 841 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Proteomics International Laboratories has a GF Score™ of 13/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Proteomics International Laboratories' Days Sales Outstanding compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Proteomics International Laboratories ranks #786 out of 841 companies for Days Sales Outstanding. This places Proteomics International Laboratories in the lower half of its industry. The industry median Days Sales Outstanding is 68.98. Proteomics International Laboratories' value of 107.22 is 55.4% above this benchmark. Historically, Proteomics International Laboratories' own Days Sales Outstanding has ranged from 64.24 to 460.19 over the past decade. While the company's 10-year median is 106.55 vs. the industry median of 68.98, Proteomics International Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 68.98, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Proteomics International Laboratories's current Days Sales Outstanding of 107.22 is 55.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Proteomics International Laboratories and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 68.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Proteomics International Laboratories's current Days Sales Outstanding is 107.22, which is near median its own 10-year median of 106.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Proteomics International Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Proteomics International Laboratories (PIQLF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.39, compared to a current price of $0.12 — trading 68% below its estimated fair value. The current Days Sales Outstanding is 107.22, which is near median its 10-year median of 106.55 and 55.4% above the Biotechnology industry median of 68.98. Proteomics International Laboratories' overall GF Score™ is 13/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Proteomics International Laboratories (PIQLF), the current Days Sales Outstanding is 107.22 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Proteomics International Laboratories (PIQLF) Overvalued in 2026?
Based on GuruFocus' analysis, Proteomics International Laboratories stock appears to be undervalued.
The current stock price of $0.12 is trading 68% below its estimated GF Value™ of $0.39.
GuruFocus considers Proteomics International Laboratories to be Possible Value Trap.
Key valuation signals for PIQLF:
Days Sales Outstanding: 107.22 (near median its 10-year median of 106.55)
GF Value™: $0.39 vs. price of $0.12 (68% below fair value)
Industry Position: 55.4% above the Biotechnology median (#786 of 841)
No single metric tells the full story. See the PIQLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Proteomics International Laboratories Ltd is a biological research and drug discovery company. It is a pioneering medical technology company operating at the forefront of predictive diagnostics and precision medicine. The Company specialises in proteomics-the industrial-scale study of the structure and function of proteins. Its pipeline includes Promarker, Pipeline PromarkerD, PromarkerEndo, PromarkerEso, and OxiDx.
13GF Score
Get the complete analysis for PIQLF
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PIQLF has been successfully added to your 
